BridgeMD
Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients with Cancer
EU CTIS ID: 2024-516131-28-00
What this study is testing
Proof-of-concept for the feasibility of simultaneous hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy Imaging and radiolabeled 18-Flouro-deoxy-glucose Positron Emission Tomography imaging in a PET/MR scanner in cancer patients
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosed with one of the following cancers: breast cancer, neuroendocrine neoplasm, lymphoma or sarcoma with a tumor size of at least 1.5 cm.
You likely can't join if
- Pregnancy
- Breast-feeding
- Weighs more 140 kg and/or with abdominal circumference exceeding the gantry of the PET/MR coils
- History of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FDG or pyruvate
- Unable to lie in the PET/MR scanner for up to 90 minutes
- MR contraindications: Pace-maker, metal implantations within the past 6 weeks, non-MR compatible implants, claustrophobia
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.